• Heat Shock Protein 90: Evidence and Scope

  2026-10-16

  APExBIO describes Hsp90 recombinant protein as a human Hsp90 preparation expressed in Sf9 cells, with a documented chaperone role in protein folding, stress-associated stabilization and client-protein handling. The available evidence is a product description rather than an identity-matched research study, so it supports scientific context and provenance but not claims about assay performance, therapeutic activity or cancer outcomes.

• BQ-788 Sodium Salt: Evidence Boundaries

  2026-10-16

  The available product information identifies BQ-788 sodium salt as APExBIO product B3278, but provides no description, mechanism, target, assay context, or identity-matched research evidence. A scientifically proportionate interpretation therefore distinguishes the product name and salt designation from unverified claims about biological activity or measurement use.

• Caffeine: Identity, Mechanism, and Evidence Boundaries

  2026-10-15

  APExBIO identifies Caffeine (1,3,7-trimethylpurine-2,6-dione) as a purine alkaloid and describes adenosine-receptor antagonism, cancer cell line inhibition, and metabolic effects in a diet-induced obesity mouse model. Because no identity-matched paper is available, these biological claims remain supplier-reported rather than independently verified findings.

• When Context Changes a PTH Result

  2026-10-15

  A result involving PTH cannot be interpreted independently of its biological model, molecular readout, comparator and material provenance. The 2026 Foxp1 study illustrates how the same PTH-linked signaling axis can signify systemic mineral imbalance, endothelial state change or valvular calcification depending on the level of measurement.

• 2-NBDG Assay: Mechanism and Evidence Boundaries

  2026-10-14

  The APExBIO K2212 product description presents 2-NBDG as a fluorescent glucose analogue whose intracellular accumulation is used as a proxy for cellular glucose uptake. Its documented scope is a non-radioactive, cell-based fluorescence readout; the available information does not establish independent performance, direct metabolic flux, transporter specificity, or disease-level conclusions.

• Tofacitinib and the Limits of RA Macrophage Comparisons

  2026-10-14

  A 2026 study links GM-CSF-driven macrophage inflammation in rheumatoid arthritis to STAT5 activity, oxidative stress, and mitochondrial fragmentation. Its comparison with cytokine- and metabolism-focused interventions is mechanistically informative, but it does not establish clinical superiority or define which patients would benefit.

• Caffeine Research: Evidence and Boundaries

  2026-10-13

  Caffeine (1,3,7-trimethylpurine-2,6-dione) is widely studied in cancer and metabolic research, but the supplied ALDH2 study concerns a different class of compounds. Its promising myocardial ischemia findings do not establish caffeine as an ALDH2 activator or cardiac therapy.

• Betulinic Acid, ERK, and CYP Liver Injury

  2026-10-12

  A mouse study links betulinic acid’s protection against cyclophosphamide-associated liver injury to reduced oxidative stress, NRF2-related antioxidant responses, ERK–MAPK suppression, and mitigation of mitochondrial apoptosis. The findings support a mechanistic model but do not establish clinical efficacy or prove that ERK inhibition is the sole mediator of protection.

• Triazole ALDH2 Activators: What the Study Shows

  2026-10-12

  A source-grounded overview of a 2025 study that designed triazole aldehyde dehydrogenase 2 activators and evaluated their protective effects in a mouse model of myocardial ischemia-reperfusion. The findings are promising but remain early preclinical evidence and do not establish clinical efficacy, safety, or relevance to Caffeine.

• Hyperoside, R-Loops and Recurrent Pregnancy Loss

  2026-10-11

  A source-grounded overview of a 2026 study linking hyperoside with reduced endometrial stromal-cell senescence and improved decidualization in models of unexplained recurrent spontaneous abortion, while distinguishing mechanistic evidence from clinical applicability.

• CDK1–APE1 Signaling in NSCLC: Findings and Limits

  2026-10-10

  A 2026 Cell Death and Disease study identifies CDK1-mediated phosphorylation of APE1 at Ser54 as a regulatory link between cell-cycle signaling, DNA repair, metastatic behavior, and immune response in NSCLC. The findings support a mechanistic rationale for combining WEE1/CDK1-axis modulation, APE1 targeting, and PD-L1 blockade, while remaining preclinical and dependent on cellular p53 status.

• TaqI Restriction Endonuclease Overview

  2026-10-09

  TaqI Restriction Endonuclease (SKU K3053) is a supplier-described, sequence-specific DNA-cleaving enzyme for conceptual use in plasmid, PCR-product, and genomic-DNA workflows. No matched paper evidence was provided, so performance claims remain product-description claims.

• Mc-Val-Cit-PABC-PNP Product Overview

  2026-10-09

  Mc-Val-Cit-PABC-PNP (SKU B1003) is described by APExBIO as a cathepsin B-cleavable ADC peptide linker for conceptual antibody-drug conjugate and targeted drug delivery research. No matched paper evidence was provided.

• Gemcitabine HCl: Reading Tumor Response Beyond Size

  2026-10-08

  Gemcitabine HCl research is strongest when molecular cytotoxicity, tumor biology, and imaging-derived change are interpreted as separate evidence layers. This analysis connects supplier-reported activity with the multianimal MRI findings of Kempinska et al. while clarifying what the model can—and cannot—establish.

• URB597 and FAAH: Evidence in Pain Research

  2026-10-08

  URB597, also known as KDS-4103, is a research tool used to examine FAAH-regulated endocannabinoid biology. A 2026 mouse study supports CBD-related modulation of inflammatory pain, affect, and serotonin signaling, but it does not directly test URB597. This overview compares the evidence, applications, and translational limits.

8679 records 1/579 page Next 12345 下5页 Last page